JP6669645B2 - 新規な鎮痛組成物 - Google Patents

新規な鎮痛組成物 Download PDF

Info

Publication number
JP6669645B2
JP6669645B2 JP2016502723A JP2016502723A JP6669645B2 JP 6669645 B2 JP6669645 B2 JP 6669645B2 JP 2016502723 A JP2016502723 A JP 2016502723A JP 2016502723 A JP2016502723 A JP 2016502723A JP 6669645 B2 JP6669645 B2 JP 6669645B2
Authority
JP
Japan
Prior art keywords
composition
hpc
isoflurane
acid
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016502723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513727A5 (https=
JP2016513727A (ja
Inventor
ダングォーレ スペイクヴィシャス
ダングォーレ スペイクヴィシャス
ヘザー ジャイルズ
ヘザー ジャイルズ
テリー ファーマー
テリー ファーマー
Original Assignee
ベイポジェニックス インコーポレイテッド
ベイポジェニックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイポジェニックス インコーポレイテッド, ベイポジェニックス インコーポレイテッド filed Critical ベイポジェニックス インコーポレイテッド
Publication of JP2016513727A publication Critical patent/JP2016513727A/ja
Publication of JP2016513727A5 publication Critical patent/JP2016513727A5/ja
Application granted granted Critical
Publication of JP6669645B2 publication Critical patent/JP6669645B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2016502723A 2013-03-15 2014-03-14 新規な鎮痛組成物 Active JP6669645B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361792383P 2013-03-15 2013-03-15
US61/792,383 2013-03-15
US201361814485P 2013-04-22 2013-04-22
US61/814,485 2013-04-22
PCT/US2014/028169 WO2014143964A2 (en) 2013-03-15 2014-03-14 Novel analgesic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019202439A Division JP2020037574A (ja) 2013-03-15 2019-11-07 新規な鎮痛組成物

Publications (3)

Publication Number Publication Date
JP2016513727A JP2016513727A (ja) 2016-05-16
JP2016513727A5 JP2016513727A5 (https=) 2017-03-16
JP6669645B2 true JP6669645B2 (ja) 2020-03-18

Family

ID=51538291

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016502723A Active JP6669645B2 (ja) 2013-03-15 2014-03-14 新規な鎮痛組成物
JP2019202439A Pending JP2020037574A (ja) 2013-03-15 2019-11-07 新規な鎮痛組成物
JP2021213648A Active JP7410114B2 (ja) 2013-03-15 2021-12-28 新規な鎮痛組成物
JP2023215692A Pending JP2024026453A (ja) 2013-03-15 2023-12-21 新規な鎮痛組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019202439A Pending JP2020037574A (ja) 2013-03-15 2019-11-07 新規な鎮痛組成物
JP2021213648A Active JP7410114B2 (ja) 2013-03-15 2021-12-28 新規な鎮痛組成物
JP2023215692A Pending JP2024026453A (ja) 2013-03-15 2023-12-21 新規な鎮痛組成物

Country Status (10)

Country Link
US (5) US9655867B2 (https=)
EP (2) EP2968214B1 (https=)
JP (4) JP6669645B2 (https=)
CN (3) CN113712911A (https=)
AU (4) AU2014227996B2 (https=)
CA (2) CA2906072C (https=)
DK (1) DK2968214T3 (https=)
ES (1) ES2873964T3 (https=)
PL (1) PL2968214T3 (https=)
WO (1) WO2014143964A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2968214T3 (pl) * 2013-03-15 2021-11-02 Newvapogen, Inc. Nowe kompozycje przeciwbólowe
CA2955229C (en) * 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3325062A4 (en) 2015-07-20 2019-03-13 Medical Developments International Limited INHALER FOR INHALABLE LIQUIDS
WO2017011867A1 (en) 2015-07-20 2017-01-26 Medical Developments International Limited Inhaler device for inhalable liquids
WO2017011865A1 (en) 2015-07-20 2017-01-26 Medical Developments International Limited Inhaler device for inhalable liquids
US9554998B1 (en) 2015-08-04 2017-01-31 Damaso Fernandez Gines Composition of analgesic bioadhesive healing microspheres
CA3019582A1 (en) 2016-03-31 2017-10-05 Smartech Topical, Inc. Delivery system
AU2017325107B2 (en) 2016-09-06 2022-10-06 Medical Developments International Limited Inhaler device for inhalable liquids
GB201706969D0 (en) * 2017-05-02 2017-06-14 Medherant Ltd Formulation
CN107693560A (zh) * 2017-09-13 2018-02-16 冯威 一种具有镇痛功能的药学组合物
US11446237B2 (en) * 2019-03-08 2022-09-20 Taro Pharmaceutical Industries Ltd. Stable topical compositions of fenoldopam
CN110090197A (zh) * 2019-04-19 2019-08-06 广州芮一生物科技有限公司 一种可成膜的麻醉面膜膏
US20220347132A1 (en) * 2019-09-19 2022-11-03 Celista Pharmaceuticals Llc Sprayable liquid lidocaine solution
JP7515582B2 (ja) * 2019-11-06 2024-07-12 スマーテック トピカル，インコーポレイテッド シクロオキシゲナーゼ阻害剤の局所配合剤およびその使用
WO2021134029A1 (en) * 2019-12-24 2021-07-01 Ampersand Biopharmaceuticals, Inc. Topical nicotine for smoking cessation
EP4103151A1 (en) * 2020-02-11 2022-12-21 Taro Pharmaceutical Industries Ltd. Compositions comprising desoximetasone and tazarotene
EP4333826A4 (en) * 2021-05-05 2025-03-12 Smartech Topical, Inc. TOPICAL NAPROXEN FORMULATIONS AND THEIR USES
CN113289172B (zh) * 2021-05-31 2023-11-03 成都中医药大学附属医院 用于治疗急诊创伤性疼痛的芳香化甲氧氟烷吸入装置
EP4522112A1 (en) 2022-05-13 2025-03-19 Laboratorios Gebro Pharma, S.A. Pharmaceutical composition for topical administration comprising a volatile anaesthetic

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3216897A (en) * 1961-11-02 1965-11-09 Air Reduction Injectable anesthetic
AR206458A1 (es) 1975-03-17 1976-07-23 Minnesota Mining & Mfg Materiales de hoja termograficas y fototermograficas
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
JPS62281814A (ja) * 1986-05-27 1987-12-07 Teisan Seiyaku Kk 徐放化貼付剤
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5114715A (en) 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
US5114714A (en) 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
US5120561A (en) 1991-04-25 1992-06-09 American Lecithin Company Food composition and method
US5283372A (en) 1991-12-04 1994-02-01 Anaquest, Inc. Preparation of purified optical isomers of desflurane
US6007838A (en) 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
CA2500310C (en) 2002-10-11 2013-03-12 Baxter International, Inc. Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics
ATE365034T1 (de) 2003-09-10 2007-07-15 Cristalia Prod Quimicos Farm Stabile pharmazeutische zusammensetzung einer fluorether-verbindung für die anästhesie, verfahren zur stabilisierung einer fluorether- verbindung, verwendung eines stabilisierungsmittels zum ausschluss des abbaus einer fluorether-verbindung
US20050079147A1 (en) 2003-10-14 2005-04-14 Bernard Delaey Wound healing compositions and uses
CA2663857C (en) * 2006-09-20 2017-10-31 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
CN101522180A (zh) * 2006-09-20 2009-09-02 得克萨斯大学体系董事会 用于区域麻醉和/和疼痛缓解的递送挥发性麻醉剂的方法
JP2008288365A (ja) * 2007-05-17 2008-11-27 Mitsubishi Electric Corp 半導体装置
EP2244783B1 (en) * 2008-01-22 2019-12-18 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
PL2244737T3 (pl) * 2008-01-22 2020-05-18 The Board Of Regents Of The University Of Texas System Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu
US7736537B1 (en) * 2008-01-24 2010-06-15 Mainstream Engineering Corp. Replacement solvents having improved properties for refrigeration flushes
WO2009117489A1 (en) 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
US8193232B2 (en) * 2009-02-13 2012-06-05 Topica Pharmaceuticals, Inc. Anti-fungal formulation
WO2010112974A2 (en) * 2009-03-31 2010-10-07 Freescale Semiconductor, Inc. System for tree sequence testing of a device and method for tree sequence testing of a device in a test framework architecture
CN109394689A (zh) * 2009-05-05 2019-03-01 德州大学系统董事会 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法
US8498853B2 (en) * 2009-07-20 2013-07-30 Exxonmobil Upstream Research Company Petrophysical method for predicting plastic mechanical properties in rock formations
CN101791291B (zh) * 2010-04-02 2011-12-28 徐州医学院 七氟醚静脉微乳剂及其制备方法
EP2723325A4 (en) * 2011-06-24 2015-03-11 Vapogenix Inc NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES
RU2013155713A (ru) * 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран
WO2013016511A1 (en) * 2011-07-27 2013-01-31 University Of Miami Stable liquid formulations of volatile gas anesthetics
PL2968214T3 (pl) * 2013-03-15 2021-11-02 Newvapogen, Inc. Nowe kompozycje przeciwbólowe

Also Published As

Publication number Publication date
US10507189B2 (en) 2019-12-17
AU2014227996A1 (en) 2015-10-08
AU2020220122A1 (en) 2020-09-03
EP3854389A1 (en) 2021-07-28
PL2968214T3 (pl) 2021-11-02
US20210077423A1 (en) 2021-03-18
CN105611921A (zh) 2016-05-25
JP2020037574A (ja) 2020-03-12
AU2018264078B2 (en) 2020-05-28
EP2968214A2 (en) 2016-01-20
WO2014143964A3 (en) 2014-11-20
JP2022031534A (ja) 2022-02-18
ES2873964T3 (es) 2021-11-04
US20160022603A1 (en) 2016-01-28
US20180250242A1 (en) 2018-09-06
CA3179312C (en) 2025-07-08
AU2018264078A1 (en) 2018-12-06
JP2016513727A (ja) 2016-05-16
US10071065B2 (en) 2018-09-11
EP2968214B1 (en) 2021-03-10
US11304913B2 (en) 2022-04-19
EP2968214A4 (en) 2017-04-12
AU2022204105A1 (en) 2022-06-30
CA2906072C (en) 2023-01-10
US10688062B2 (en) 2020-06-23
US20170231924A1 (en) 2017-08-17
JP7410114B2 (ja) 2024-01-09
CA3179312A1 (en) 2014-09-18
WO2014143964A2 (en) 2014-09-18
JP2024026453A (ja) 2024-02-28
CN112933036A (zh) 2021-06-11
CA2906072A1 (en) 2014-09-18
US20200022928A1 (en) 2020-01-23
US9655867B2 (en) 2017-05-23
CN113712911A (zh) 2021-11-30
AU2014227996B2 (en) 2018-08-23
DK2968214T3 (da) 2021-06-07

Similar Documents

Publication Publication Date Title
JP7410114B2 (ja) 新規な鎮痛組成物
JP5952357B2 (ja) 揮発性麻酔薬組成物およびその使用
CA2760775C (en) Novel formulations of volatile anesthetics and methods of use for reducing inflammation
US20220378719A1 (en) Analgesic compositions comprising halogenated volatile compounds
AU2017203066B2 (en) Volatile anesthetic compositions and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191202

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200227

R150 Certificate of patent or registration of utility model

Ref document number: 6669645

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250